| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Epidemiology and Prevention |
Department of Cancer Cell Biology, Harvard School of Public Health, Boston, Massachusetts 02115 [H. H. N., K. T. K.], and Section of Biostatistics and Epidemiology, Department of Community and Family Medicine, Dartmouth Medical School, Lebanon, New Hampshire 03756 [L. A. M., M. R. K.]
| ABSTRACT |
|---|
|
|
|---|
gln variant, has been associated with several cancer-related biomarkers, suggesting it may have functional significance in exposure-induced cancers. However, results from case-control studies have yielded conflicting results. We investigated the XRCC1 arg399gln polymorphism and its interaction with carcinogen exposure in a large, population-based case-control study of non-melanoma skin cancer. Cases were derived from an incident survey of all newly diagnosed non-melanoma skin cancer in New Hampshire, and controls were population based and frequency matched to cases on age and sex (n = 1176). Exposure information was derived from a detailed interviewer-administered questionnaire, and XRCC1 genotype was determined from blood-derived DNA using a PCR-RFLP method. Overall, the XRCC1 homozygous variant gln399gln genotype was related to a significantly reduced risk of both basal cell [BCC; odds ratio (OR) 0.7, 95% confidence interval 0.41.0] and squamous cell carcinoma (SCC; OR 0.6, 95% confidence interval 0.30.9). There was no significant gene-environment interaction of the variant XRCC1 genotype and a history of therapeutic X-ray exposure. However, there was a statistically significant multiplicative interaction of XRCC1 genotype and lifetime number of sunburns in SCC [likelihood ratio test (2 d.f.), P < 0.02]. Although the absolute risk of SCC associated with sunburns was similar across genotypes, the relative risk of SCC associated with painful sunburn history was significantly higher for homozygous variants than wild types (OR 6.8 for gln399gln and 1.5 for arg399arg). In summary, our data show that the homozygous XRCC1 variant (gln399gln) is associated with a lower risk of non-melanoma skin cancer and suggest that the etiology of sunburn-related SCC may be significantly different by XRCC1 genotype. These data, using the classic skin carcinogenesis model, provide new insight on the role of the XRCC1 399 polymorphism in neoplasia and may help explain the conflicting results relating this polymorphism to cancer risk at various sites. | INTRODUCTION |
|---|
|
|
|---|
NMSC is primarily a disease of UV radiation exposure. However, other exposures, such as ionizing radiation (2 , 3) and arsenic (4 , 5) , can contribute to skin carcinogenesis (reviewed in Ref. 6 ). Host susceptibility factors are also clearly associated with NMSC, particularly pigmentation and the tendency to burn (7 , 8) . In addition, constitutional variation in DNA repair capacity has been associated with skin cancer occurrence (9) . However, the precise genetic factors that contribute to this reduced repair phenotype have not been elucidated.
Recent studies have demonstrated that a polymorphism in the DNA base excision repair gene XRCC1 (arg399gln) is associated with measurably reduced DNA repair capacity as assessed by the persistence of DNA adducts (10 , 11) , increased RBC Glycophorin A mutations (10) , elevated sister chromatid exchanges (11 , 12) , and prolonged cell cycle delay (13) . In addition, this same polymorphism has been reported to be associated with the occurrence of six solid tumors: head and neck cancer (14 , 15) ,4 ,5 breast cancer (16) , lung cancer (17) , bladder cancer (18) , stomach cancer (19) , and colorectal cancer (20) . However, these data do not point to a consistent role of the XRCC1 gln399gln protein, as the genotype confers increased risk in some studies (14 , 15, 16, 17 , 19 , 20) and a protective effect in others (18) ,4 ,5 whereas three other reports have indicated no cancer association (21, 22, 23) .
XRCC1 directly participates in both base excision and single-strand break repair (24 , 25) . The arg399gln polymorphism occurs at a conserved residue in the poly(ADP-ribose) polymerase binding domain of XRCC1 (26) and may alter the efficiency of repair processes. Although base excision repair does not directly repair UV photolesions, it is likely an important repair pathway for oxidative damage induced by either UV (27) or ionizing radiation exposure (28) . Therefore, we have examined the XRCC1 arg399gln polymorphism in a population-based case-control study of NMSC in New Hampshire.
| STUDY POPULATION AND METHODS |
|---|
|
|
|---|
XRCC1 Genotyping.
DNA was extracted from peripheral circulating blood specimens taken at the time of interview using Qiagen genomic DNA extraction kits. Genotyping of the XRCC1 arg399gln polymorphism was done using a PCR-RFLP method. A 171-bp fragment was amplified using the following primer pair: 5'-CCAAGTACAGCCAGGTCCTA and 5'-AGTCTGACTCCCCTCCGGAT. After a 4-min incubation at 94°C, 35 cycles of PCR were performed (94°C 30 s
58°C 30 s
72°C 30 s), followed by a 10-min extension at 72°C. The PCR product was then incubated with MspI endonuclease at 37°C overnight. The polymorphism of interest disrupts an MspI consensus sequence, rendering it resistant to digestion. Wild-type alleles were digested to 92, 61, and 18 bp (the 18-bp fragment results from a nonpolymorphic MspI site that served as an internal control for complete enzymatic digestion). Positive and negative controls also were included in each determinate of genotype.
Statistical Methods.
Crude and adjusted ORs and 95% CIs for the association of XRCC1 genotype and case status were calculated using unconditional logistic regression (29)
. All adjusted models included age, sex, and tendency to sunburn (always burn, burn then tan, or always tan). Other confounders considered included cumulative sun hours as well as hair and eye color. Two primary exposures were considered: sunburn history and therapeutic ionizing radiation. Painful sunburns were assessed by questionnaire as the number of sunburns that were painful for
2 days; this variable was then dichotomized according to the median in controls (
3 sunburns). Self report of ionizing radiation therapy was verified through medical records in 44 of 56 (79%) subjects. Ionizing radiation treatments for NMSC were not included in the analysis.
Interaction was explored multiple ways. We conducted a conventional test of interaction, a Log-likelihood test comparing a "full" model that contains both the main effects of genotypes and environment plus an (gene x environment) interaction term and a "reduced" model that does not contain the cross-product variable. The "joint" effects of gene and environment were examined using those with both low exposure and the arg399arg genotype as the referent group (30) . Using the ß estimates from this joint regression model, we assessed the relative excess risk from exposure within genotype strata. This was accomplished using proc LINCOM statements in STATA.
| RESULTS |
|---|
|
|
|---|
BCC cases tended to be younger and SCC cases older than controls (Table 1)
. In addition, both case groups were significantly more likely to burn rather than tan after their first sun exposure of the season. As reported previously, case status was associated with a history of therapeutic ionizing radiation (2)
. A history of painful sunburns was also significantly more prevalent in cases than controls (Table 1)
.
|
2 = 3.4, P = 0.07). There were no significant associations of XRCC1 genotype and demographic variables (data not shown). The prevalence of the homozygous variant gln399gln genotype was 16.5% (72 of 432) in controls, 11.8% (59 of 499) in BCC cases, and 10.2% (25 of 246) in SCC cases (Table 2)
|
Additional analysis of interaction involved construction of a "joint model" of sunburn and XRCC1 genotype (Table 3)
. The referent group was set as those with zero to two painful sunburns and the arg/arg genotype (according to our a priori hypothesis). For both BCC and SCC, the gln/gln genotype, in the absence of multiple sunburns, was associated with significantly reduced risk [BCC OR = 0.5 (95% CI 0.30.9), SCC OR = 0.3 (95% CI 0.10.6)]. Three or more sunburns were associated with increased risk, irrespective of XRCC1 genotype. Finally, we assessed the relative risk from sunburn within genotype strata using the ß estimates from the joint model (Table 4)
. Within wild-type (arg/arg) and heterozygous (arg/gln) strata, there was a modest risk of SCC with three or more painful sunburns (OR = 1.5 and 1.6, respectively). However, among those who were XRCC1 gln399gln, the relative risk of SCC associated with a high number of sunburns was approximately seven compared with those having fewer than three sunburns [OR = 6.8 (95% CI 2.419.2)]. A case-only analysis of interaction was consistent with the model using controls [OR = 3.1 (95% CI 1.18.7)], indicating the observed interaction was not driven by population stratification in the controls.
|
|
| DISCUSSION |
|---|
|
|
|---|
This model is consistent with the results of our gene-environment analysis. Repeated sunburns may be viewed as the probability of having a field of p53 mutant cells [as suggested by the findings of Ouhtit et al. (31) and Einspahr et al. (32) ], and p53 mutation abrogates keratinocyte apoptosis (33) . In the absence of repeated sunburns, the gln399gln genotype is protective (apoptosis intact). Using the model described above, once the apoptotic mechanism is ablated (after multiple sunburns), the risk of skin cancer among the gln399gln should be markedly higher, reflecting the reduced repair phenotype, whereas the risk among those with arg alleles would not be dramatically altered. Our strata-specific ORs (arg399arg = 1.5 and gln399gln = 6.8) are strikingly consistent with this model.
There are, of course, other explanations for both our main gene effect and gene-environment interaction. These include possible linkage to another important polymorphism, differential effects of the polymorphism by carcinogen dose, and population stratification (although our case-case analysis suggests this is unlikely). Other groups have investigated this polymorphism for gene-environment interaction with conflicting findings. In a case-control study of breast cancer (16) , the XRCC1 polymorphism modified the effects of smoking and ionizing radiation such that the exposure-associated risks were highest among African-Americans with the arg399arg genotype. Stern et al. (18) suggested that heavy exposure might saturate the effects of the polymorphism; the 399gln genotype was associated with reduced bladder cancer risk but only among light smokers. Divine et al. (17) proposed that the penetrance of the 399gln genotype may be greater in those with high exposure. This possibility is also consistent with our data, as well as that of Sturgis et al. (14) and Stern et al. (18) .
In sum, we have found that the main effect of the gln399gln genotype in skin cancer is risk reduction. Our findings of gene-environment interaction suggest two interpretations: (a) the absolute risk of SCC associated with sunburn is constant across genotypes; and (b) the relative risk associated with multiple sunburns is significantly elevated among gln399gln individuals, while being only modestly elevated among those with the 399arg allele. We have posited a model of the XRCC1 polymorphism that may explain the inconsistent findings across studies. For each tumor type, the biological pathway responsible for the induction of apoptosis and the inactivation of this mechanism may impact both the ability to detect as well as the direction of the XRCC1-disease association. Furthermore, if the polymorphism functions differentially under conditions of "high" and "low" exposure, it will require significant numbers of cases in each exposure group to detect the differential effects of the XRCC1 polymorphism. Finally, this likely will vary significantly not only by carcinogen exposure but also by disease, ethnicity, and geography. Additional in vitro and large population-based studies are needed to test this model, both in skin cancer as well as other exposure-induced cancers.
| ACKNOWLEDGMENTS |
|---|
| FOOTNOTES |
|---|
1 Supported by Grants CA82354 and CA57494 from the National Cancer Institute and ES00002 from the National Institute Environmental Health Science Center. ![]()
2 To whom requests for reprints should be addressed, at Department of Cancer Cell Biology, Harvard School of Public Health, Boston, MA 02115. E-mail: hnelson{at}hsph.harvard.edu ![]()
3 The abbreviations used are: NMSC, non-melanoma skin cancer; BCC, basal cell carcinoma; SCC, squamous cell cancer; CI, confidence interval; OR, odds ratio. ![]()
4 A. Olshan, M. A. Watshon, M. C. Weissler, and D. A. Bell. XRCC1 polymorphisms and head and neck cancer, submitted for publication. ![]()
5 E. Peters, N. E. Mueller, M. Posner, and K. T. Kelsey. The Arg/Gln XRCC1 DNA repair gene polymorphism and head and neck cancer, submitted for publication. ![]()
Received 4/30/01. Accepted 10/29/01.
| REFERENCES |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
M. Tanori, M. Mancuso, E. Pasquali, S. Leonardi, S. Rebessi, V. Di Majo, M.-N. Guilly, F. Giangaspero, V. Covelli, S. Pazzaglia, et al. PARP-1 cooperates with Ptc1 to suppress medulloblastoma and basal cell carcinoma Carcinogenesis, October 1, 2008; 29(10): 1911 - 1919. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. M. McCarty, T. J. Smith, W. Zhou, E. Gonzalez, Q. Quamruzzaman, M. Rahman, G. Mahiuddin, L. Ryan, L. Su, and D. C. Christiani Polymorphisms in XPD (Asp312Asn and Lys751Gln) genes, sunburn and arsenic-related skin lesions Carcinogenesis, August 1, 2007; 28(8): 1697 - 1702. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. V. Breton, W. Zhou, M. L. Kile, E.A. Houseman, Q. Quamruzzaman, M. Rahman, G. Mahiuddin, and D. C. Christiani Susceptibility to arsenic-induced skin lesions from polymorphisms in base excision repair genes Carcinogenesis, July 1, 2007; 28(7): 1520 - 1525. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. F. Giachino, P. Ghio, S. Regazzoni, G. Mandrile, S. Novello, G. Selvaggi, D. Gregori, M. DeMarchi, and G. V. Scagliotti Prospective Assessment of XPD Lys751Gln and XRCC1 Arg399Gln Single Nucleotide Polymorphisms in Lung Cancer Clin. Cancer Res., May 15, 2007; 13(10): 2876 - 2881. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. E. Povey, F. Darakhshan, K. Robertson, Y. Bisset, M. Mekky, J. Rees, V. Doherty, G. Kavanagh, N. Anderson, H. Campbell, et al. DNA repair gene polymorphisms and genetic predisposition to cutaneous melanoma Carcinogenesis, May 1, 2007; 28(5): 1087 - 1093. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Zhu, M. Lai, H. Yang, J. Lin, M. Huang, H.B. Grossman, C. P. Dinney, and X. Wu Genotypes, haplotypes and diplotypes of XPC and risk of bladder cancer Carcinogenesis, March 1, 2007; 28(3): 698 - 703. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. A. Hill, S. S. Wang, J. R. Cerhan, S. Davis, W. Cozen, R. K. Severson, P. Hartge, S. Wacholder, M. Yeager, S. J. Chanock, et al. Risk of non-Hodgkin lymphoma (NHL) in relation to germline variation in DNA repair and related genes Blood, November 1, 2006; 108(9): 3161 - 3167. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Li, Z. Liu, L.-E Wang, S. S. Strom, J. E. Lee, J. E. Gershenwald, M. I. Ross, P. F. Mansfield, J. N. Cormier, V. G. Prieto, et al. Genetic variants of the ADPRT, XRCC1 and APE1 genes and risk of cutaneous melanoma Carcinogenesis, September 1, 2006; 27(9): 1894 - 1901. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. K. Thirumaran, J. L. Bermejo, P. Rudnai, E. Gurzau, K. Koppova, W. Goessler, M. Vahter, G. S. Leonardi, F. Clemens, T. Fletcher, et al. Single nucleotide polymorphisms in DNA repair genes and basal cell carcinoma of skin Carcinogenesis, August 1, 2006; 27(8): 1676 - 1681. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. L. Miller, M. R. Karagas, P. Kraft, D. J. Hunter, P. J. Catalano, S. H. Byler, and H. H. Nelson XPA, haplotypes, and risk of basal and squamous cell carcinoma Carcinogenesis, August 1, 2006; 27(8): 1670 - 1675. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Ekstrom Smedby, C. M. Lindgren, H. Hjalgrim, K. Humphreys, C. Schollkopf, E. T. Chang, G. Roos, L. P. Ryder, K. I. Falk, J. Palmgren, et al. Variation in DNA Repair Genes ERCC2, XRCC1, and XRCC3 and Risk of Follicular Lymphoma. Cancer Epidemiol. Biomarkers Prev., February 1, 2006; 15(2): 258 - 265. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. J. Hung, J. Hall, P. Brennan, and P. Boffetta Genetic Polymorphisms in the Base Excision Repair Pathway and Cancer Risk: A HuGE Review Am. J. Epidemiol., November 15, 2005; 162(10): 925 - 942. [Abstract] [Full Text] [PDF] |
||||
![]() |
W.-Y. Huang, W.-H. Chow, N. Rothman, J. Lissowska, V. Llaca, M. Yeager, W. Zatonski, and R. B. Hayes Selected DNA repair polymorphisms and gastric cancer in Poland Carcinogenesis, August 1, 2005; 26(8): 1354 - 1359. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. Hu, H. Ma, F. Chen, Q. Wei, and H. Shen XRCC1 Polymorphisms and Cancer Risk: A Meta-analysis of 38 Case-Control Studies Cancer Epidemiol. Biomarkers Prev., July 1, 2005; 14(7): 1810 - 1818. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y.-T. Jeon, J. W. Kim, N.-H. Park, Y.-S. Song, S.-B. Kang, and H.-P. Lee DNA repair gene XRCC1 Arg399Gln polymorphism is associated with increased risk of uterine leiomyoma Hum. Reprod., June 1, 2005; 20(6): 1586 - 1589. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Shen, M. D. Gammon, M. B. Terry, L. Wang, Q. Wang, F. Zhang, S. L. Teitelbaum, S. M. Eng, S. K. Sagiv, M. M. Gaudet, et al. Polymorphisms in XRCC1 Modify the Association between Polycyclic Aromatic Hydrocarbon-DNA Adducts, Cigarette Smoking, Dietary Antioxidants, and Breast Cancer Risk Cancer Epidemiol. Biomarkers Prev., February 1, 2005; 14(2): 336 - 342. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. T. Kelsey, S. Park, H. H. Nelson, and M. R. Karagas A Population-Based Case-Control Study of the XRCC1 Arg399Gln Polymorphism and Susceptibility to Bladder Cancer Cancer Epidemiol. Biomarkers Prev., August 1, 2004; 13(8): 1337 - 1341. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. C. Figueiredo, J. A. Knight, L. Briollais, I. L. Andrulis, and H. Ozcelik Polymorphisms XRCC1-R399Q and XRCC3-T241M and the Risk of Breast Cancer at the Ontario Site of the Breast Cancer Family Registry Cancer Epidemiol. Biomarkers Prev., April 1, 2004; 13(4): 583 - 591. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Zhu, M. R. Spitz, C. I. Amos, J. Lin, M. B. Schabath, and X. Wu An Evolutionary Perspective on Single-Nucleotide Polymorphism Screening in Molecular Cancer Epidemiology Cancer Res., March 15, 2004; 64(6): 2251 - 2257. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. A. Rybicki, D. V. Conti, A. Moreira, M. Cicek, G. Casey, and J. S. Witte DNA Repair Gene XRCC1 and XPD Polymorphisms and Risk of Prostate Cancer Cancer Epidemiol. Biomarkers Prev., January 1, 2004; 13(1): 23 - 29. [Abstract] [Full Text] [PDF] |
||||
![]() |
X.-O. Shu, Q. Cai, Y.-T. Gao, W. Wen, F. Jin, and W. Zheng A Population-Based Case-Control Study of the Arg399Gln Polymorphism in DNA Repair Gene XRCC1 and Risk of Breast Cancer Cancer Epidemiol. Biomarkers Prev., December 1, 2003; 12(12): 1462 - 1467. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Moullan, D. G. Cox, S. Angele, P. Romestaing, J.-P. Gerard, and J. Hall Polymorphisms in the DNA Repair Gene XRCC1, Breast Cancer Risk, and Response to Radiotherapy Cancer Epidemiol. Biomarkers Prev., November 1, 2003; 12(11): 1168 - 1174. [Abstract] [Full Text] |
||||
![]() |
M.-W. Yu, S.-Y. Yang, I-J. Pan, C.-L. Lin, C.-J. Liu, Y.-F. Liaw, S.-M. Lin, P.-J. Chen, S.-D. Lee, and C.-J. Chen Polymorphisms in XRCC1 and Glutathione S-Transferase Genes and Hepatitis B-Related Hepatocellular Carcinoma J Natl Cancer Inst, October 1, 2003; 95(19): 1485 - 1488. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. L. Goode, C. M. Ulrich, and J. D. Potter Polymorphisms in DNA Repair Genes and Associations with Cancer Risk Cancer Epidemiol. Biomarkers Prev., December 1, 2002; 11(12): 1513 - 1530. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Seedhouse, R. Bainton, M. Lewis, A. Harding, N. Russell, and E. Das-Gupta The genotype distribution of the XRCC1 gene indicates a role for base excision repair in the development of therapy-related acute myeloblastic leukemia Blood, November 15, 2002; 100(10): 3761 - 3766. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. W. Mohrenweiser, T. Xi, J. Vazquez-Matias, and I. M. Jones Identification of 127Amino Acid Substitution Variants in Screening 37 DNA Repair Genes in Humans Cancer Epidemiol. Biomarkers Prev., October 1, 2002; 11(10): 1054 - 1064. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. J. Duell, E. A. Holly, P. M. Bracci, J. K. Wiencke, and K. T. Kelsey A Population-based Study of the Arg399Gln Polymorphism in X-Ray Repair Cross- Complementing Group 1 (XRCC1) and Risk of Pancreatic Adenocarcinoma Cancer Res., August 15, 2002; 62(16): 4630 - 4636. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||